We evaluated the potential of a thermoresponsive
hydrogel consisting of
conjugated linoleic acid-coupled
Pluronic F-127 (Plu-CLA) as a controlled release, intraperitoneal delivery system for
docetaxel with the aim of treating peritoneal dissemination of
gastric cancer. Previously, we established a peritoneal
metastasis model that involves the injection of BALB/c mice with TMK1 human
gastric cancer cells. One week after the TMK1 cells were injected, the mice were injected intraperitoneally with
docetaxel alone or
docetaxel-loaded Plu-CLA.
Tumor progression and response to
therapy were monitored by micro-positron emission tomography. The total number of peritoneal
tumors and the
ascites volume were also measured. Compared with
docetaxel alone, the combination of
docetaxel and Plu-CLA (
docetaxel-Plu-CLA) significantly and synergistically reduced
tumor cell survival.
Docetaxel-Plu-CLA showed excellent anti-
tumor activity, inducing apoptosis more potently than
docetaxel alone.
Docetaxel-Plu-CLA also significantly reduced the number of peritoneal metastatic nodules and increased survival in the peritoneal
gastric cancer xenograft model. Our results show that intraperitoneal administration of
docetaxel-Plu-CLA synergistically inhibits peritoneal
metastasis and prolongs survival in a peritoneal
gastric cancer model. Therefore, Plu-CLA is a potential intraperitoneal-route carrier for hydrophobic
docetaxel for the effective treatment of peritoneal metastatic
gastric cancer.